China NMPA Approves Promega's MSI Detection Kit as Companion Diagnostic for KEYTRUDA
核心洞察
China's National Medical Products Administration has approved Promega's OncoMate® MSI (搜索) Detection Kit as a Class III in vitro diagnostic device to identify MSI-High solid tumor patients for KEYTRUDA treatment.
This marks the first Promega companion diagnostic to receive NMPA approval, addressing China's significant cancer burden where solid tumors represent the vast majority of diagnoses nationwide.
The PCR-based assay will support precision oncology strategies by evaluating microsatellite instability status in tumor tissue to guide treatment decisions for advanced solid tumor patients.
China's National Medical Products Administration (NMPA) has approved Promega Corporation (搜索)'s OncoMate® Microsatellite Instability (MSI (搜索)) Detection Kit as a Class III in vitro diagnostic medical device, marking a significant milestone in precision oncology for the Chinese market. The diagnostic is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumor patients for treatment with KEYTRUDA® (pembrolizumab), Merck & Co. (搜索)'s anti-PD-1 (搜索) therapy.
This approval represents the first Promega companion diagnostic to receive NMPA clearance, addressing a critical need in China's healthcare system where the country continues to face one of the world's highest cancer burdens.
Addressing China's Cancer Challenge
China's oncology landscape presents substantial challenges, with solid tumors representing the vast majority of cancer diagnoses nationwide. Despite advances in oncology care, most patients with advanced solid tumors ultimately progress after first-line therapy, creating a critical need for tools that can guide more effective alternative treatment strategies.
"This approval represents a step toward more personalized and effective cancer treatment in China," says Alok Sharma, Global Clinical Market Director at Promega. "We are proud to collaborate with pharmaceutical companies to deliver global solutions that expand access to innovative technologies and life-saving, effective therapies."
Technical Specifications and Clinical Application
The OncoMate® MSI (搜索) Detection Kit is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status serves as a crucial biomarker that can be used to guide treatment decisions and support precision oncology strategies in solid tumors. The diagnostic tool enables healthcare providers to identify patients whose tumors exhibit microsatellite instability, a characteristic that may predict response to immunotherapy treatments like KEYTRUDA.
Regulatory Collaboration and Global Expansion
The approval was achieved through a collaboration with Merck & Co. (搜索), Inc., Rahway, NJ, USA, which markets KEYTRUDA. This partnership reflects a shared commitment to improving access to diagnostics that guide therapeutic decision-making in oncology care.
Promega's MSI (搜索) technology has demonstrated regulatory success across multiple markets, having received additional approvals in China, the European Union, and the United States. The company's OncoMate® MSI Dx Analysis System was recently approved by the FDA as a companion diagnostic designed to identify patients with microsatellite stable (MSS) endometrial carcinoma who may benefit from treatment with KEYTRUDA plus LENVIMA® (Lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.
Market Availability
The OncoMate® MSI (搜索) Detection Kit will soon be available for purchase in China, providing oncologists and pathologists with a validated tool for precision medicine approaches in solid tumor management. This availability is expected to enhance the implementation of personalized treatment strategies for Chinese cancer patients, particularly those with advanced solid tumors who have limited therapeutic options after first-line treatment failure.